<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491621</url>
  </required_header>
  <id_info>
    <org_study_id>0501106</org_study_id>
    <nct_id>NCT00491621</nct_id>
  </id_info>
  <brief_title>Evaluation of Diagnostic Value of Molecular Markers in Renal Cancer</brief_title>
  <acronym>CMM</acronym>
  <official_title>Study Evaluating the Interest of Cytology-molecular Tumor Markers Association for the Diagnostic Strategy in Adult Kidney Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal cancer is frequent and its diagnosis mainly dependant on imaging. More than 50% of
      renal tumors are currently diagnosed without symptoms. However, 20% of small solid tumors are
      benign and this percentage is much higher in atypical cystic tumors Bosniak II and III, where
      76% and 59% are benign respectively. Determining the malignancy by imaging in these cases is
      difficult and sometimes impossible. The fine needle aspiration (FNA) cytology or biopsy is
      necessary. The diagnostic sensitivity and specificity with biopsy are high, but the potential
      tumor contamination is a major risk. The FNA cytology is simple and safe, but its sensitivity
      is about 50%. We are conducting a multicentric prospective study to add the molecular markers
      in FNA cytology as a new diagnostic method in imaging-indeterminate renal tumors.

      Four molecular markers including MN/CA9, vimentin, KIT, and S100A1 will be studied. These
      four markers have been reported to have a differential diagnostic value in renal tumors.
      MN/CA9 and vimentin are often found in conventional renal cancers. KIT is frequently
      expressed in renal oncocytomas and chromophobe renal cancers. S100A1 may further distinguish
      renal oncocytoma from chromophobe renal cancer. These markers will be analyzed by real time
      polymerase chain reaction (RT-PCR).

      The aim of this study is to evaluate the diagnostic performance of the association
      cytology-molecular markers in imaging-indeterminate renal tumors (small solid tumors and
      cystic tumors ≥ Bosniak III). About 156 patients will be included in five French clinical
      centers including Saint-Etienne, Marseille, Grenoble, Toulouse, and Nancy.

      The expected results will improve the preoperative diagnostic accuracy in renal tumors.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No enough inclusion. The aim is no longer relevant. The sponsor decided to stop this study.
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histologic diagnostic (tumor)</measure>
    <time_frame>after surgery or biopsy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytology-molecular tumor markers association diagnostic (tumor)</measure>
    <time_frame>after surgery or biopsy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular tumor markers association diagnostic (blood + urine)</measure>
    <time_frame>3, 6, 9, 12, 15, 18, 21 and 24 months after biopsy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Kidney Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>surgery or biopsy of the kidney tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery or biopsy of the kidney tumor</intervention_name>
    <description>surgery or biopsy of the kidney tumor</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of kidney tumor &lt; 4 cm

          -  Cystic kidney tumor (Bosniak &gt; IIF)

          -  Consent signed

        Exclusion Criteria:

          -  Benign tumor confirmed

          -  Impossibility to do abdominal pelvic ultra-sound or abdominal thoracic scanner

          -  Contraindication for renal puncture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques TOSTAIN, PhD-MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Edouard Herriot</name>
      <address>
        <city>LYON cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM Hôpital Salvator</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Li G, Cuilleron M, Cottier M, Gentil-Perret A, Lambert C, Genin C, Tostain J. The use of MN/CA9 gene expression in identifying malignant solid renal tumors. Eur Urol. 2006 Feb;49(2):401-5. Epub 2005 Dec 19.</citation>
    <PMID>16387417</PMID>
  </reference>
  <reference>
    <citation>Li G, Cuilleron M, Gentil-Perret A, Cottier M, Passebosc-Faure K, Lambert C, Genin C, Tostain J. Rapid and sensitive detection of messenger RNA expression for molecular differential diagnosis of renal cell carcinoma. Clin Cancer Res. 2003 Dec 15;9(17):6441-6.</citation>
    <PMID>14695146</PMID>
  </reference>
  <reference>
    <citation>Li G, Barthelemy A, Feng G, Gentil-Perret A, Peoc'h M, Genin C, Tostain J. S100A1: a powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma. Histopathology. 2007 Apr;50(5):642-7.</citation>
    <PMID>17394501</PMID>
  </reference>
  <reference>
    <citation>Li G, Feng G, Gentil-Perret A, Genin C, Tostain J. CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy. Clin Exp Metastasis. 2007;24(3):149-55. Epub 2007 Mar 28.</citation>
    <PMID>17390110</PMID>
  </reference>
  <reference>
    <citation>Li G, Gentil-Perret A, Lambert C, Genin C, Tostain J. S100A1 and KIT gene expressions in common subtypes of renal tumours. Eur J Surg Oncol. 2005 Apr;31(3):299-303.</citation>
    <PMID>15780567</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney</keyword>
  <keyword>tumor</keyword>
  <keyword>Molecular Markers</keyword>
  <keyword>Cytology</keyword>
  <keyword>Histology</keyword>
  <keyword>Cystic kidney tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

